SLS - SELLAS Life Sciences Group, Inc.
NEXT EARNINGS:
May 11, 2026
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$2.80
DETAILS
HIGH:
$3.20
LOW:
$2.40
MEDIAN:
$2.80
CONSENSUS:
$2.80
DOWNSIDE:
37.43%
Market Cap:
637.43M
Volume:
10,099,512
Avg Volume:
9,267,989
52 Week Range:
0.95-6.14
Sector:
Healthcare
Industry:
Biotechnology
Beta:
2.21
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
15
IPO Date:
2008-03-12
EPS (TTM):
-0.25
P/E Ratio:
-15.30
Revenue (TTM):
N/A
Total Assets:
78.34M
Total Debt:
1.00M
Cash & Equiv:
71.89M
Rev Growth (5Y):
N/A
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-39.6%
Debt/Equity:
0.01
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-03-19 | $-0.05 | $-0.06 | +21.0% | — | — | — |
| 2025-11-12 | $-0.06 | $-0.06 | +5.3% | — | — | — |
| 2025-08-12 | $-0.07 | $-0.08 | +16.0% | — | — | — |
| 2025-05-13 | $-0.07 | $-0.10 | +30.0% | — | — | — |
| 2025-03-20 | $-0.08 | $-0.11 | +27.3% | — | — | — |
| 2024-11-13 | $-0.10 | $-0.13 | +23.1% | — | — | — |
| 2024-08-13 | $-0.13 | $-0.16 | +18.8% | — | — | — |
| 2024-05-14 | $-0.21 | $-0.16 | -31.2% | — | — | — |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 1.00M | 7.60M | 1.90M | 0 | 0 | 0 | 0 | 0 | 9.32M |
| Net Income | (26.86M) | (30.88M) | (37.34M) | (41.30M) | (20.70M) | (16.76M) | (19.29M) | (27.67M) | (23.75M) | (23.55M) | (63.90M) | (36.61M) |
| EPS | -0.25 | -0.50 | -1.34 | -2.13 | -1.34 | -2.11 | -10.92 | -157.72 | -521.91 | -933.13 | -411.55 | -1022.20 |
| Total Assets | 78.34M | 19.43M | 6.22M | 20.94M | 26.43M | 46.05M | 16.61M | 16.91M | 33.53M | 65.81M | 82.14M | 80.49M |
| Total Debt | 1.00M | 1.00M | 906,000 | 945,000 | 808,000 | 991,000 | 217,000 | 0 | 10.99M | 16.40M | 4.74M | 8.40M |
| Cash & Equivalents | 71.89M | 13.89M | 2.53M | 17.12M | 21.45M | 35.30M | 7.28M | 5.34M | 2.32M | 18.08M | 29.73M | 23.65M |
| Operating Cash Flow | (28.39M) | (35.40M) | (31.41M) | (23.81M) | (26.02M) | (10.42M) | (17.64M) | (30.42M) | (10.99M) | (44.91M) | (48.16M) | (42.87M) |
| Free Cash Flow | (28.39M) | (35.40M) | (36.91M) | (28.31M) | (26.02M) | (10.42M) | (17.64M) | (30.42M) | (10.99M) | (44.92M) | (48.31M) | (48.40M) |
| FCF per Share | -0.26 | -0.58 | -1.33 | -1.46 | -1.68 | -1.31 | -9.99 | -173.84 | -244.20 | -2495.61 | -2415.65 | -1351.46 |
| Book Value | 70.87M | 9.46M | (7.98M) | 4.85M | 20.35M | 27.96M | 6.09M | 5.25M | 2.07M | 28.66M | 13.51M | 37.06M |
| Cash & ST Investments | 71.89M | 13.89M | 2.53M | 17.12M | 21.45M | 35.30M | 7.28M | 5.34M | 2.32M | 18.08M | 29.73M | 23.65M |
| ROC Equity | -0.38 | -3.26 | N/A | -8.51 | -1.02 | -0.60 | -3.17 | -5.28 | -11.48 | -0.82 | -4.73 | -0.99 |